스피노사드

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Cats (per this specific monograph's label status)
• Dogs with known pork or soy allergies (chewable tablets contain pork proteins and hydrolyzed soy)
• Dogs and cats weighing < 1.2 kg
• Dogs and cats < 14 weeks of age
• Dogs with MDR1 mutation (relative contraindication due to increased risk of adverse effects)

이상반응

• Vomiting (most common)
• Depression/lethargy
• Anorexia
• Ataxia
• Diarrhea
• Pruritus
• Trembling
• Hypersalivation
• Seizures (rare)
• Vomiting (occasional)
• Lethargy (rare)
• Diarrhoea (rare)
• Anorexia (rare)
• Ataxia (rare)

약물 상호작용

• Ivermectin · Concurrent use with high extra-label doses of ivermectin (e.g., for demodicosis) increases the risk of neurotoxicity. However, spinosad is safe to use with standard low-dose heartworm preventatives.
• Macrocyclic lactones (e.g., avermectins, ivermectin) · Increased risk of severe neurological toxicity. Do not use in combination. · major
• Digoxin · Competition for P-glycoprotein efflux pump, potentially increasing digoxin levels. · moderate
• Doxorubicin · Competition for P-glycoprotein efflux pump, potentially increasing doxorubicin toxicity. · moderate

모니터링

• Flea control efficacy
• Adverse gastrointestinal or neurologic effects
• Efficacy of flea control
• Gastrointestinal tolerance (vomiting)
• Adverse neurological signs

과용량

Spinosad has a wide margin of safety. The oral LD50 in mice is >5000 mg/kg. In canine dose tolerance studies (up to 16.7X the normal dose for 10 days), the primary sign was **routine vomiting**. No significant changes in hematology or coagulation were noted, though mild elevations in ALT and phospholipidosis (vacuolation) of lymphoid tissue occurred.